Illumina's TruSight Oncology Comprehensive Assay Approval
The FDA's recent approval of Illumina's TruSight Oncology Comprehensive Assay represents a significant breakthrough in cancer diagnostics. This pioneering diagnostic kit, the first of its kind, provides comprehensive genomic profiling (CGP) applicable across various cancer types. PreCheck Health Services is excited to launch this transformative test, branded as SolidTumorCheck+, marking a new era in precision oncology and improving patient care.
The Impact of TruSight Oncology Comprehensive Test
This approval is a major milestone for both healthcare providers and patients. The TruSight Oncology Comprehensive test can analyze over 500 gene biomarkers, offering valuable insights that empower clinicians to create personalized treatment plans. This new assay enables rapid genomic profiling, effectively meeting the needs of patients.
Understanding TruSight Oncology Comprehensive
This groundbreaking FDA-approved diagnostic kit transforms the field of cancer genomics. By profiling more than 500 gene biomarkers, it helps identify genetic mutations that drive cancer across different tumor types. A key feature is its pan-cancer companion diagnostic capability, which allows for tailored therapy recommendations based on an individual patient's genomic profile.
Features and Benefits of SolidTumorCheck+
SolidTumorCheck+ offers a variety of advantages, providing deep insights into cancer diagnostics:
- Comprehensive Genomic Profiling (CGP): The SolidTumorCheck+ test delivers an extensive genomic analysis covering a wide range of cancers, revealing crucial insights into the molecular drivers of the disease.
- Detecting Over 500 Gene Biomarkers: This test evaluates more than 500 gene biomarkers, resulting in a thorough assessment that encourages personalized treatment opportunities.
- Pan-Cancer Companion Diagnostic Claims: SolidTumorCheck+ features pan-cancer companion diagnostics that enhance the matching of therapies to patients, supporting a personalized cancer treatment journey.
- Access to Precision Oncology: The SolidTumorCheck+ test broadens access to precision oncology services, allowing patients to receive advanced cancer care closer to home.
Benefits for Clinical Laboratories
In addition to improving patient care, SolidTumorCheck+ provides significant benefits to clinical laboratories:
- Local Access to Advanced Diagnostics: With this offering, PreCheck Health Services establishes itself as a leader in community-based healthcare by providing specialized cancer testing.
- Accelerated Turnaround Times: Local processing of tests leads to shorter wait times, enabling quicker treatment decisions.
- Strengthening Lab Reputation: By adopting advanced genomic profiling, PreCheck Health Services enhances its reputation as an innovator in cancer diagnostics.
Frequently Asked Questions
How does this test benefit patients?
SolidTumorCheck+ facilitates precision medicine by customizing treatments according to a patient's unique cancer profile. Localized testing results in faster diagnoses and timely treatment planning.
Which cancers does the test address?
SolidTumorCheck+ is designed to be versatile, addressing a broad spectrum of cancer types by identifying genetic alterations across different tumors.
What role does the pan-cancer companion diagnostic play?
This component of the test identifies the most effective targeted therapies based on a patient's specific genetic makeup, ensuring personalized treatment options.
Conclusion
The FDA's approval of the TruSight Oncology Comprehensive test marks a significant advancement in cancer diagnostics and treatment approaches. The introduction of this advanced assay by PreCheck Health Services enhances access to personalized treatment options for patients in their local communities. With its comprehensive capabilities and pan-cancer companion diagnostic claims, SolidTumorCheck+ is set to revolutionize cancer care, paving the way for better patient outcomes.
PreCheck Health Services’ dedication to providing this innovative test positions them at the forefront of advancements in cancer genomics. Their collaboration in processing the FDA-approved SolidTumorCheck+ not only supports essential research but also offers vital resources that can greatly impact the lives of patients they serve.
Contact Information
PreCheck Health Services, Inc.
100 Biscayne Blvd, Suite 1611, Miami, FL 33132
+1 (214) 680-5000
